Immix Biopharma, Inc. IMMX 深 沪
已收盘 02-06 16:00:00 美东时间
6.74
+0.790
+13.28%
华盛通- 最 高6.8725
- 今 开6.09
- 成交量 86.72万股
- 最 低 6.06
- 昨 收 5.95
- 总市值 3.57亿
- 52周最高 7.73
- 市盈率 静 --
- 换手率 1.64%
- 52周最低 1.34
- 委 比 50.70%
- 总股本 5295.51万
- 历史最高 8.68
- 量 比 1.07
- 振 幅 13.66%
- 历史最低 0.68
- 每 手 1
- 风险率 1.39%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Immix Biopharma Granted Breakthrough Therapy Designation From FDA To NXC-201 To Treat Relapsed/Refractory AL Amyloidosis
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough
01-28 21:48
Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities
Immix Biopharma Inc (NASDAQ: IMMX) shares are trading lower Monday after the company filed a new shelf registration statement.
01-12 23:48
美股大行评级 | 花旗上调苹果目标价升至330美元；GPCR、KYMR、MAMA、TERN、WVE等获多家机构上调目标价
今日重点评级关注：Chardan Capital：维持Senti Biosciences"买入"评级，目标价从12美元升至13美元；Guggenheim：维持Praxis Precision Medicine"买入"评级，目标价从540美元升至760美元
2025-12-10 10:33
Immix Biopharma To Present Phase 1/2 Interim Results From US NXC-201 NEXICART-2 Trial In Relapsed/Refractory AL Amyloidosis At ASH 2025
- Oral presentation Sunday, December 7, at ASH 2025 -LOS ANGELES, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL
2025-11-03 21:48
Immix Biopharma To Present An Abstract On Its Therapy NXC-201 At The ASH 67th Annual Meeting December 6–9, 2025, In Orlando, Florida
Immix Biopharma, Inc. ("ImmixBio", "Company", "We" or "Us" or "IMMX"), the global leader in relapsed/refractory AL Amyloidosis, today announced that it will present a NXC-201 abstract at the upcoming American Society of
2025-10-08 04:10
Immix Biopharma Surpasses 50% Enrollment In NEXICART-2 Trial For CAR-T NXC-201 In Relapsed/Refractory AL Amyloidosis, Advancing Toward BLA Submission
– On track for first FDA Biologics License Application (BLA) approved cell therapy in orphan indication relapsed/refractory AL Amyloidosis –Los Angeles, CA, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc.
2025-09-19 01:32
美股大行评级 | 潜在涨幅280.95%！HC Wainwright & Co.上调Immix Biopharma目标价至8美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Immix Biopharma"买入"评级，目标价从7美元升至8美元；Maxim Group：上调CNS Pharma评级至"买入"，目标价20美元
2025-09-15 11:13
Nancy T. Chang, Proven Biotechnology Leader, Joins Immix Biopharma Board of Directors
Dr. Nancy T. Chang, former CEO of Tanox, Inc., joins Immix Biopharma's board and Goose Capital investment. She led XOLAIR® and other successful drugs to market, generating over $5 billion in sales. Immix Biopharma is advancing NXC-201, a CAR-T therapy for AL Amyloidosis, with promising clinical results and designation as RMAT and ODD.
2025-09-11 13:15
Immix Biopharma Completes Private Placement Transaction
The latest announcement is out from Immix Biopharma ( ($IMMX) ). On September 5...
2025-09-09 04:36
Immix Biopharma Gains Strategic Investment From Goose Capital And Dr. Nancy T. Chang; Financial Terms Not Disclosed
Immix Biopharma, Inc. ("Immix", "Company", "We" or "Us" or "IMMX"), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that it has received
2025-09-09 04:08
